Information Provided By: 
Fly News Breaks for May 16, 2016
NXTM
May 16, 2016 | 06:50 EDT
Piper Jaffray analyst Matt O'Brien says he disagrees with the two main bear arguments regarding NxStage Medical. The analyst disagrees with the notion that NxStage's HHD growth is coming mostly from price increases and that competition is going to significantly disrupt the company. O'Brien views NxStage as a "compelling growth story" and raised his price target for the shares to $21 from $18.50. He reiterates an Overweight rating on the shares.
News For NXTM From the Last 2 Days
There are no results for your query NXTM
